[REVISION HISTORY]
Research into diabetic kidney disease treatments
5 recorded revisions of this situation.
What changed
2026-10-25 16:58 UTC → 2026-10-26 19:39 UTC ·
added
removed
Scientific research into diabetic kidney disease (DKD) is focusing on novel therapeutic targets, improved monitoring markers, and optimized medication timing. Studies in the ‘Chinese Journal of Natural Medicines’ suggest the plant compound hederagenin may protect kidney health by activating anti-aging genes to combat cellular senescence. Additionally, researchers are investigating protein tyrosine phosphatases (PTP) as potential therapeutic targets. Clinical observations emphasize combining medication classes—such as RAS blockers, SGLT2 inhibitors, mineralocorticoid receptor antagonists, and GLP-1 receptor agonists—to delay dialysis. While the BESTMED study indicates GLP-1 and SGLT-2 inhibitors can slow renal decline more effectively than traditional therapies, concerns persist regarding the off-label use of GLP-1 weight-loss drugs and risks like ketoacidosis. Newer research highlights advancements in monitoring and administration. In South Korea, non-albumin proteinuria (NAP) has been identified as a potential marker for monitoring patient response to finerenone. Furthermore, data from National Taiwan University Hospital suggests that the timing of SGLT-2 inhibitor administration may be critical for patients recovering from acute kidney injury. At the American Society of Nephrology’s Kidney Week 2026, data from the FIND-CKD clinical trial showed data for finerenone showed it slowed eGFR decline in non-diabetic CKD patients, even when used alongside SGLT2 inhibitors. A phase 2 trial of balcinrenone combined with dapagliflozin also demonstrated reduced systolic blood pressure in stage 3 CKD patients. Real-world analyses Regarding GLP-1 receptor agonists, new data on elecoglipron indicated a reduction in South Korea also linked urine albumin-to-creatinine ratio (UACR) in type 2 diabetes patients. In geriatric populations, real-world data involving over 10,000 adults aged 80 or older suggested SGLT2 inhibitors inhibitor therapy was linked to lower an 18% reduction in all-cause mortality, though risks of for acute kidney injury and cardiovascular certain cardiac events in older adults. Despite these remain. Digital health advancements, significant treatment gaps remain, particularly among women, older adults, such as using large language models (LLMs) for prior authorization letters and those with advanced CKD. risk-stratification models, were also highlighted to improve therapy uptake.
Versions
- 2026-10-26 19:39 UTC Research into diabetic kidney disease treatments
- 2026-10-25 16:58 UTC Research into diabetic kidney disease treatments
- 2026-10-12 07:20 UTC Research into diabetic kidney disease treatments
- 2026-09-29 03:38 UTC Research into diabetic kidney disease treatments
- 2026-09-28 03:28 UTC Research into diabetic kidney disease treatments
- 2026-09-13 01:36 UTC Research into diabetic kidney disease treatments
Select a version to see what changed compared to the one before it.